- Report
- October 2024
- 195 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- March 2025
- 92 Pages
Global
From €5324EUR$5,600USD£4,472GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- May 2024
- 200 Pages
Global
From €3945EUR$4,150USD£3,314GBP
- Report
- July 2024
- 151 Pages
Global
From €4040EUR$4,250USD£3,394GBP
- Report
- November 2022
- 141 Pages
Global
From €4706EUR$4,950USD£3,953GBP
- Report
- August 2023
- 150 Pages
Global
From €5656EUR$5,950USD£4,752GBP
- Report
- January 2024
- 181 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- April 2023
- 117 Pages
Global
From €4516EUR$4,750USD£3,794GBP
- Report
- January 2024
- 150 Pages
Global
From €4611EUR$4,850USD£3,873GBP
The Hemato Oncology Testing market within the Diagnostics industry is focused on the development and commercialization of tests that detect and monitor cancer and other hematological diseases. These tests are used to diagnose, monitor, and treat a variety of conditions, including leukemia, lymphoma, and myeloma. They are also used to detect and monitor the progression of cancer and other hematological diseases. The tests are used to identify genetic mutations, detect the presence of cancer cells, and monitor the effectiveness of treatments.
The Hemato Oncology Testing market is highly competitive, with a number of companies offering a variety of tests. Some of the major players in the market include Abbott Laboratories, Becton Dickinson, Bio-Rad Laboratories, Cepheid, GenMark Diagnostics, Hologic, Illumina, Myriad Genetics, Qiagen, Roche Diagnostics, and Thermo Fisher Scientific. Show Less Read more
